Related Experiment Video

Updated: Oct 23, 2025

Identification of RNAs Engaged in Direct RNA-RNA Interaction with a Long Non-Coding RNA
07:24

Identification of RNAs Engaged in Direct RNA-RNA Interaction with a Long Non-Coding RNA

Published on: July 9, 2021

2.5K

[Identification of Novel Differentially Expressing Long Non- Coding RNAs with Oncogenic Potential]

O I Brovkina1,2,3, I V Pronina1, L A Uroshlev1,4

  • 1Research Institute of General Pathology and Pathophysiology, Moscow, 125315 Russia.

Molekuliarnaia Biologiia
|August 25, 2021
PubMed

Insights

New research identifies long non-coding RNAs (lncRNAs) as key players in ovarian cancer. Lnc-CCL28 and SNHG17 show increased levels in tumors, with LINC00152 and NEAT1 overexpression confirmed, linking them to advanced disease stages and metastasis.

Area of Science:

  • Molecular Biology
  • Genomics
  • Cancer Research

Background:

  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their regulatory roles in gene expression.
  • Dysregulation of lncRNAs is implicated in various human diseases, including cancer.

Purpose of the Study:

  • To identify novel differentially expressed lncRNAs in ovarian tumors using deep machine learning.
  • To investigate the potential of specific lncRNAs as biomarkers for ovarian cancer diagnosis and prognosis.

Main Methods:

  • Deep machine learning was employed to identify differentially expressed lncRNAs in ovarian tumor samples.
  • Reverse transcription quantitative polymerase chain reaction (RT-PCR) was used to validate transcript levels of selected lncRNAs (lnc-CCL28, SNHG17, LINC00152, NEAT1).

Main Results:

  • Four novel lncRNAs (TMEM92-AS1, FAM222A-AS, TXLNB, and lnc-CCL28) were identified as differentially expressed in ovarian tumors.
  • For the first time, increased levels of lnc-CCL28 and SNHG17 were observed in ovarian tumors.
  • Overexpression of LINC00152 and NEAT1 was confirmed, and their levels were significantly associated with advanced stages and metastasis in ovarian cancer.

Conclusions:

  • lnc-CCL28 and SNHG17 represent novel potential biomarkers for ovarian cancer.
  • The overexpression of LINC00152 and lnc-CCL28 is linked to disease progression and metastasis, suggesting their involvement in ovarian carcinogenesis.
Keywords:
deep machine learningdifferential expressionlnc-CCL28long noncoding RNAsoncogenic potentialprognostic marker

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

773
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.1K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.2K